A Review of Research Progress on Agathis dammara and Its Application Prospects for Cardiovascular Diseases and Fatty Liver Disease

2020 ◽  
Vol 20 ◽  
Author(s):  
Anyi Wang ◽  
Shanshan Yue ◽  
Ankang Peng ◽  
Rong Qi
Keyword(s):  
Liver Disease ◽  
Cardiovascular Diseases ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Modern Society ◽  
Research Progress ◽  
Myocardial Ischemia Reperfusion ◽  
Application Prospects

: Cardiovascular diseases and fatty liver disease have become the leading causes of death in modern society. However, currently existing drugs do not solve all issues related to these diseases; thus, it is expected that more potential drugs for clinical use will be developed. Undeniably, natural products have attracted increasing attention. It is of great significance to identify effective active monomer components for drug discovery and disease prevention. As a pure natural product, Agathis dammara (AD) has antioxidant, hypolipidemic, hypoglycemic, antitumor and anti-inflammatory activities. However, at present, there are few reports regarding the effects of AD on chronic inflammatory cardiovascular diseases such as aneurysm, atherosclerosis, myocardial ischemia-reperfusion injury, and cardiac hypertrophy and liver diseases such as fatty liver disease. AD and products derived from it have very broad application prospects for cardiovascular diseases and fatty liver disease.

Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease

Hepatology ◽  
2004 ◽  
Vol 40 (4) ◽  
pp. 933-941 ◽  
Author(s):  
Feng Hong ◽  
Svetlana Radaeva ◽  
Hong-na Pan ◽  
Zhigang Tian ◽  
Richard Veech ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Reperfusion Injury ◽  
Hepatic Steatosis ◽  
Interleukin 6 ◽  
Fatty Liver Disease ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion

scholarly journals New Developments in Exosomal lncRNAs in Cardiovascular Diseases

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhu Yuan ◽  
Weiqiang Huang
Keyword(s):  
Cardiovascular Diseases ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Cell Types ◽  
Research Progress ◽  
Therapeutic Effects ◽  
Myocardial Ischemia Reperfusion Injury ◽  
Non Coding Rnas ◽  
Myocardial Ischemia Reperfusion ◽  
Rheumatic Heart

Long non-coding RNAs (lncRNAs) are non-coding RNAs with lengths >200 nt and are involved in the occurrence and development of cardiovascular diseases (CVDs). Exosomes are secreted and produced by various cell types. Exosome contents include various ncRNAs, proteins and lipids. Exosomes are also important mediators of intercellular communication. The proportion of lncRNAs in exosomes is low, but increasing evidence suggests that exosomal lncRNAs play important roles in CVDs. We focused on research progress in exosomal lncRNAs in atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, cardiac angiogenesis, cardiac aging, rheumatic heart disease, and chronic kidney disease combined with CVD. The potential diagnostic and therapeutic effects of exosomal lncRNAs in CVDs are summarized based on preclinical studies involving animal and cell models and circulating exosomes in clinical patients. Finally, the challenges and possible prospects of exosomes and exosomal lncRNAs in clinical applications related to CVD are discussed.

scholarly journals Gut Microbiota Changes in Nonalcoholic Fatty Liver Disease and Concomitant Cardiovascular Diseases

2020 ◽  
Author(s):  
Olena H. Kurinna
Keyword(s):  
Liver Disease ◽  
Cardiovascular Diseases ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Statistical Significance ◽  
Microbiota Composition ◽  
Nonalcoholic Fatty Liver ◽  
Gut Microbiota Composition

AbstractNonalcoholic fatty liver disease (NAFLD) bears serious economic consequences for the health care system worldwide and Ukraine, in particular. Cardiovascular diseases (CVD) are the main cause of mortality in NAFLD patients. Changes in the gut microbiota composition can be regarded as a potential mechanism of CVD in NAFLD patients.The purpose of this work was to investigate changes in major gut microbiota phylotypes, Bacteroidetes, Firmicutes and Actinobacteria with quantification of Firmicutes/Bacteroidetes in NAFLD patients with concomitant CVD.The author enrolled 120 NAFLD subjects (25 with concomitant arterial hypertension (AH) and 24 with coronary artery disease (CAD)). The gut microbiota composition was assessed by qPCR.Resultsthe author found a marked tendency towards an increase in the concentration of Bacteroidetes (by 37.11% and 21.30%, respectively) with a decrease in Firmicutes (by 7.38% and 7.77%, respectively) in both groups with comorbid CAD and AH with the identified changes not reaching a statistical significance. The author quantified a statistically significant decrease in the concentration of Actinobacteria in patients with NAFLD with concomitant CAD at 41.37% (p<0.05) as compared with those with an isolated NAFLD. In patients with concomitant AH, the content of Actinobacteria dropped by 12.35%, which was statistically insignificant.Conclusionsthe author established changes in the intestinal microbiota, namely decrease in Actinobacteria in patients with CAD, which requires further research.

Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases

2017 ◽  
Vol 41 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Nima Motamed ◽  
Behnam Rabiee ◽  
Hossein Poustchi ◽  
Babak Dehestani ◽  
Gholam Reza Hemasi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Cardiovascular Diseases ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document